Synergism between asymmetric dimethylarginine (ADMA) and a genetic marker of uric acid in CKD progression

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 25, Issue 2, 2015, Pages 167-172

  Testa, A ^a   Mallamaci, F ^a   Leonardis, D ^a   Spoto, B ^a   Pisano, A ^a   Sanguedolce, M C ^a   Tripepi, G ^a   Zoccali, C ^a   Audino, A ^b   Bruzzese, V ^b   Caglioti, A ^b   Campo, S ^b   Caridi, G ^b   Caruso, A ^b   Chiarella, S ^b   Cicchetti, T ^b   Curti, C ^b   Anello, D ^b   Giuseppe, Enia ^b   Fabiano, F ^b   Fatuzzo, P ^b   Fersini, S ^b   Garozzo, M ^b   Grandinetti, F ^b   Guido, A ^b   Gullo, M ^b   Maimone, I ^b   Mancuso, F ^b   Mannino, M ^b   Marino, F ^b   Natale, G ^b   Palma, L ^b   Papalia, T ^b   Parisi, T ^b   Parlongo, G ^b   Pinciaroli, A ^b   Pinna, M ^b   Plutino, D ^b   Maurizio, Postorino ^b   Pugliese, M ^b   Rapisarda, F ^b   Reina, A ^b   Santoro, O ^b   Tramontana, D ^b   more..

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b NONE

Author keywords

ADMA; CKD progression; Epidemiology; Polymorphism; Uric acid

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE TRANSPORTER; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; ARGININE; CALCIUM; CREATININE; GENETIC MARKER; HEMOGLOBIN; N,N-DIMETHYLARGININE; SERUM ALBUMIN; SLC2A9 PROTEIN, HUMAN; URIC ACID;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BOOTSTRAPPING; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DISEASE COURSE; DNA POLYMORPHISM; DRUG BIOAVAILABILITY; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERURICEMIA; INCIDENCE; KIDNEY INJURY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; PROTEINURIA; URIC ACID BLOOD LEVEL; URINALYSIS; AGED; ALLELE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOASSAY; BLOOD; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; GENETIC MARKER; GENETICS; METABOLISM; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ALLELES; ARGININE; C-REACTIVE PROTEIN; CALCIUM; CASE-CONTROL STUDIES; COHORT STUDIES; CREATININE; DISEASE PROGRESSION; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; GENETIC MARKERS; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; HEMOGLOBINS; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY, CHRONIC; SERUM ALBUMIN; URIC ACID;

EID: 84922011299     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2014.10.016     Document Type: Article

References (31)

1. Testa A., Mallamaci F., Spoto B., Pisano A., Sanguedolce M.C., Tripepi G., et al. Association of a polymorphism in a gene encoding a urate transporter with CKD progression. Clin J Am Soc Nephrol 2014, 9:1059-1065.
2. Kolz M., Johnson T., Sanna S., Teumer A., Vitart V., Perola M., et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 2009, 5:e1000504.
3. Zoccali C. Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move. J Hypertens 2006, 24:611-619.
4. Fujimi-Hayashida A., Ueda S., Yamagishi S., Kaida Y., Ando R., Nakayama Y., et al. Association of asymmetric dimethylarginine with severity of kidney injury and decline in kidney function in IgA nephropathy. Am J Nephrol 2011, 33:1-6.
5. Von Haehling S., Bode-Boger S.M., Martens-Lobenhoffer J., Rauchhaus M., Schefold J.C., Genth-Zotz S., et al. Elevated levels of asymmetric dimethylarginine in chronic heart failure: a pathophysiologic link between oxygen radical load and impaired vasodilator capacity and the therapeutic effect of allopurinol. Clin Pharmacol Ther 2010, 88:506-512.
6. Kuwahata S., Hamasaki S., Ishida S., Kataoka T., Yoshikawa A., Orihara K., et al. Effect of uric acid on coronary microvascular endothelial function in women: association with eGFR and ADMA. J Atheroscler Thromb 2010, 17:259-269.
7. Fliser D., Kronenberg F., Kielstein J.T., Morath C., Bode-Böger S.M., Haller H., et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005, 16:2456-2461.
8. Ravani P., Tripepi G., Malberti F., Testa S., Mallamaci F., Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005, 16:2449-2455.
9. Johnson R.J., Nakagawa T., Jalal D., Sánchez-Lozada L.G., Kang D.H., Ritz E. Uric acid and chronic kidney disease: which is chasing which?. Nephrol Dial Transpl 2013, 28:2221-2228.
10. Kang D.H., Park S.K., Lee I.K., Johnson R.J. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005, 16:3553-3562.
11. Leiper J., Nandi M., Torondel B., Murray-Rust J., Malaki M., O'Hara B., et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 2007, 13:198-203.
12. Zoccali C., Maio R., Mallamaci F., Sesti G., Perticone F. Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 2006, 17:1466-1471.
13. Yilmaz M.I., Saglam M., Caglar K., Cakir E., Sonmez A., Ozgurtas T., et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 2006, 47:42-50.
14. Gschwend S., Buikema H., Navis G., Henning R.H., de Zeeuw D., van Dokkum R.P., et al. Endothelial dilatory function predicts individual susceptibility to renal damage in the 5/6 nephrectomized rat. J Am Soc Nephrol 2002, 13:2909-2915.
15. Zoccali C., Leonardis D., Enia G., Postorino M., Mallamaci F. MAURO study working group. The MAURO study: multiple intervention and audit in renal diseases to optimize care. J Nephrol 2008, 21:20-22.
16. Schulze F., Wesemann R., Schwedhelm E., Sydow K., Albsmeier J., Cooke J.P., et al. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med 2004, 42:1377-1383.
17. Steyerberg E.W. Clinical prediction models 2009, 303-3049. Springer. 1st ed.
18. Iseki K., Oshiro S., Tozawa M., Iseki C., Ikemiya Y., Takishita S., et al. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 2001, 24:691-697.
19. Domrongkitchaiporn S., Sritara P., Kitiyakara C., Stitchantrakul W., Krittaphol V., Lolekha P., et al. Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study. J Am Soc Nephrol 2005, 16:791-799.
20. Obermayr R.P., Temml C., Knechtelsdorfer M., Gutjahr G., Kletzmayr J., Heiss S., et al. Predictors of new-onset decline in kidney function in a general middle-european population. Nephrol Dial Transpl 2008, 23:1265-1273.
21. Weiner D.E., Tighiouart H., Elsayed E.F., Griffith J.L., Salem D.N., Levey A.S. Uric acid and incident kidney disease in the community. J Am Soc Nephrol 2008, 19:1204-1211.
22. Bellomo G., Venanzi S., Verdura C., Saronio P., Esposito A., Timio M. Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis 2010, 56:264-272.
23. Chonchol M., Shlipak M.G., Katz R., Sarnak M.J., Newman A.B., Siscovick D.S., et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007, 50:239-247.
24. Syrjanen J., Mustonen J., Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transpl 2000, 15:34-42.
25. Siu Y.P., Leung K.T., Tong M.K., Kwan T.H. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006, 47:51-59.
26. Goicoechea M., de Vinuesa S.G., Verdalles U., Ruiz-Caro C., Ampuero J., Rincón A., et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010, 5:1388-1393.
27. Levy G.D., Rashid N., Niu F., Cheetham T.C. Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia. J Rheumatol 2014, 41:955-962.
28. Jalal D.I., Chonchol M., Chen W., Targher G. Uric acid as a target of therapy in CKD. Am J Kidney Dis 2013, 61:134-146.
29. Vaziri N.D. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 2004, 13:93-99.
30. Johnson R.J., Herrera-Acosta J., Schreiner G.F., Rodriguez-Iturbe B. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 2002, 346:913-923.
31. Schepers E., Speer T., Bode-Böger S., Fliser D., Kielstein J. Dimethylarginines ADMA and SDMA: the real water-soluble small toxins?. Semin Nephrol 2014, 34:97-105.